Studies a PSMA-1007 scan to find prostate cancer that has returned after treatment
Tests a PSMA-1007 imaging scan in adults whose prostate cancer has returned after treatment.
Plain-language title generated from the registry record
Registry title: Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer
Key facts
- Where
- Düsseldorf, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older who have a [18F]PSMA-1007 PET scan as part of their regular care for prostate cancer that came back or did not go away after treatment.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate cancer after radical treatment, with biochemical recurrence or biochemical persistence
- Earlier treatment
- Radical treatment of prostate cancer
Main reasons for not taking part
- Technical flaws in how the scan was acquired
Read by machine on 12 November 2026.
Where in Germany
- Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University DuesseldorfDüsseldorf, GermanyContact: Frederik Lars Giesel, Univ.-Prof. Dr. med.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Heinrich-Heine University, Duesseldorf
- Trial code
- NCT06657131
- Record updated
- 17 January 2025
- Original description
Following numerous retrospective studies and Phase-3-Studies with promising results, [18F]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.Read full original descriptionShow less
Diagnostic Performance and Clinical Impact of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer: a Real-World Evidence from a Monocentric, Prospective Observational Phase-4-Trial
Following numerous retrospective studies and Phase-3-Studies with promising results, [18F]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.
Inclusion: Informed Consent; Conduct of [18F]PSMA-1007 PET Imaging in the context of regular clinical care.
Exclusion: Technical Flaws in the acquisition protocol.